PD42-09 EFFECTS OF OMEGA-3-RICH FISH OIL (MAG-EPA) ON PROSTATE CANCER: PRELIMINARY RESULTS OF A CLINICAL TRIAL

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy VI1 Apr 2018PD42-09 EFFECTS OF OMEGA-3-RICH FISH OIL (MAG-EPA) ON PROSTATE CANCER: PRELIMINARY RESULTS OF A CLINICAL TRIAL Lisanne Beaudoin, Nikunj Gevariya, Karine Robitaille, Marie-Hélène Guertin, Jean-Francois Pelletier, Pierre Julien, and Vincent Fradet Lisanne BeaudoinLisanne Beaudoin More articles by this author , Nikunj GevariyaNikunj Gevariya More articles by this author , Karine RobitailleKarine Robitaille More articles by this author , Marie-Hélène GuertinMarie-Hélène Guertin More articles by this author , Jean-Francois PelletierJean-Francois Pelletier More articles by this author , Pierre JulienPierre Julien More articles by this author , and Vincent FradetVincent Fradet More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1962AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Prostate cancer (PCa) is the most common non-skin cancer in North American men. Long chain poly-unsaturated omega-3 (LCn3) fatty acids (FA), mainly eicosapentaenoic acid (EPA), would be beneficial against PCa development and progression likely via anti-inflammatory properties. A phase IIb double-blinded randomized controlled trial is currently ongoing in our research team in order to investigate the effects of an EPA-rich fish oil (MAG-EPA) supplementation on PCa proliferation, as well as on inflammation and quality of life (QoL). In the present study, we aimed to determine the MAG-EPA effects on systemic and prostate tissue inflammation, a secondary outcome of this trial. METHODS 130 patients with a Gleason greater than or equal to 7 PCa treated by radical prostatectomy (RP) were randomized to a daily intake of either MAG-EPA or placebo. The supplementation started 6 weeks before RP for up to one year after surgery. Many medical, clinical and QoL questionnaires as well as biological samples were gathered throughout the study. Without lifting the blind, systemic and local inflammation were assessed by measuring expression levels of 27 inflammatory mediators using the Bio-PlexTM technology. Cytokine levels in plasma and prostate tissue were measured at baseline, RP and 12 months for the first 30 patients who completed the study. RESULTS Preliminary analysis revealed important modulation of circulating levels over time for about half of the patients. Interestingly, we observed two distinct plasmatic cytokine profiles at RP (designated group A and group B). More than half of circulating cytokines were significantly upregulated in group A compared to group B. No significant difference was observed in the prostate tissue between patients at RP. CONCLUSIONS These first preliminary results suggest that systemic inflammation is modulated by the intervention in PCa patients over time. The analysis of the entire cohort is warranted and will likely identify LCn3 modulated cytokines in circulation and in the prostate tissue. This RCT represents a unique setting to study the LCn3 biological effects on PCa. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e817-e818 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Lisanne Beaudoin More articles by this author Nikunj Gevariya More articles by this author Karine Robitaille More articles by this author Marie-Hélène Guertin More articles by this author Jean-Francois Pelletier More articles by this author Pierre Julien More articles by this author Vincent Fradet More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...